EnteroMedics Inc. (NASDAQ:ETRM) will post its quarterly earnings results before the market opens on Tuesday, August 8th. Analysts expect EnteroMedics to post earnings of ($1.00) per share for the quarter.
EnteroMedics (NASDAQ:ETRM) last posted its quarterly earnings results on Tuesday, May 16th. The medical device company reported ($1.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.64. The company had revenue of $0.04 million during the quarter. EnteroMedics had a negative return on equity of 506.36% and a negative net margin of 3,088.74%. On average, analysts expect EnteroMedics to post $-3.97 EPS for the current fiscal year and $-2.84 EPS for the next fiscal year.
EnteroMedics Inc. (NASDAQ ETRM) opened at 3.82 on Friday. The stock’s market cap is $26.38 million. The firm has a 50 day moving average of $4.70 and a 200-day moving average of $5.56. EnteroMedics Inc. has a 12-month low of $1.75 and a 12-month high of $30.41.
Several brokerages have recently issued reports on ETRM. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $11.00 target price on shares of EnteroMedics in a report on Thursday, May 25th. Zacks Investment Research cut shares of EnteroMedics from a “buy” rating to a “hold” rating in a report on Thursday, July 20th.
COPYRIGHT VIOLATION WARNING: “EnteroMedics Inc. (ETRM) to Release Quarterly Earnings on Tuesday” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/06/enteromedics-inc-etrm-to-release-quarterly-earnings-on-tuesday.html.
EnteroMedics Company Profile
EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
